RISE and Constance Therapeutics Join Forces, Marrying Cannabis and Sexual Health
February 15th, 2018
Exclusive, News, Top News
The recent partnership between Luminor Medical Technologies Inc. (CSE: LMT), soon to be called RISE Life Science Corp., and Constance Therapeutics takes aim at two large and growing markets: legal cannabis products and sexual health. The companies have agreed to develop and market cannabis-based sexual health products, starting this year in California.
California’s cannabis revenue is projected to reach $3.7 billion in 2018 and rise to $5.1 billion in 2019, according to BDS Analytics. These revenues are poised to continue to grow as the market matures and more dispensaries and cultivation operations come online. Meanwhile, according to Grand View Research, the U.S. sexual wellness market is projected to reach $8.8 billion by 2025, driven by the aging population and the introduction of new and innovative products.
Let’s take a look at just what these two companies have planned and why it merits attention.
Constance Therapeutics is a Force in the Cannabis Industry
Constance Therapeutics (CT) was founded by Constance Finley. Her own experience with an autoimmune disease, and the negative side effects from pharmaceuticals intended to treat the disease, led her to successfully investigate and use cannabis as an alternative treatment. As a result, she founded the company and focused on creating standardized, whole plant cannabis extracts based on the documented ‘Entourage Effect’ of the cannabis plant. In essence, the Entourage Effect means that active ingredients in cannabis, like cannabinoids and terpenes, are more effective when working in conjunction with the entire chemical profile of the plant than they are in isolation.
The company, and the founder, have enjoyed tremendous success and have earned widespread respect throughout the industry. Constance Therapeutics was the first company in California to professionalize and standardize cannabis formulations for medicinal use, and recently became the first cannabis extraction producer to be awarded a manufacturing permit in the city of San Francisco. Ms. Finley herself was recently appointed to the Scientific Advisory Board of Canna Tech, a high-level, three day event series featuring the biggest thought leaders and market disruptors in medical cannabis across the globe.
Constance Therapeutics’ commitment to quality and consistency runs through the whole operation, from sustainable farming practices, to genetic consistency, to patent-pending extraction, to third-party testing of extracts, to adherence to pharmaceutical-grade best laboratory practices.
RISE and Constance Therapeutics Partner
RISE Life Science has focused on developing botanical formulations to support adult sexual health and wellness. It has a patent-pending cannabis-based formulation that lies at the heart of the CT partnership. Under the terms of the deal, RISE will build and manage a retail sales and distribution channel for both CT and RISE products in California, as well as deploy a direct sales team to sign top-tier dispensaries. CT will leverage its new research and development and manufacturing facility in San Francisco to mass produce a line of sexual health and wellness products under license to RISE to be sold through these channels. RISE expects to have a network of at least 240 dispensaries up and selling by the end of 2018.
“Constance Therapeutics represents an evidence-based process. Her company has been focused on producing scientifically derived cannabis products for the past 10 years — everything that goes through her process is completely vetted. The botanicals that are used are not haphazard; they’ve actually been tested for efficacy and for their ability to work well with cannabis components,” said RISE Life Science CEO Anton Mattadeen.
“Constance brings a solid scientific base to the formulations that we are creating — she’s making those products better and it places us in the position where we can have constant improvement as we go through the process.”
Luminor Medical Technologies Inc. (CSE: LMT) represents a compelling investment opportunity within the burgeoning cannabis industry. After partnering with Constance Therapeutics, the company is uniquely positioned to scale into California’s market with a focus on the sexual health and wellness segment of the market.
For more information, visit the company’s website at www.riselifescience.com.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please see our disclaimer below and follow the link to view our full disclosure outlining compensation: http://www.cannabisfn.com/legal-disclaimer/
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: http://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.